Multiple sclerosis (MS) is a chronic, autoimmune, and neurodegenerative disease of the
central nervous system (CNS) that affects myelin. The etiology of MS is unclear, although a …

Multiple sclerosis (MS) is a highly heterogeneous demyelinating disease of the central
nervous system (CNS) that needs for reliable biomarkers to foresee disease severity. Recently, …

Background The increasing number of treatments that are now available to manage patients
with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used …

Despite the pharmacological arsenal approved for Multiple Sclerosis (MS), there are
treatment-reluctant patients for whom cell therapy appears as the only therapeutic alternative. …

Background Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis.
It is released by endothelial cells, but also expressed by neurons and glial cells in the …

Multiple Sclerosis (MS) is a highly heterogeneous demyelinating disease of the central
nervous system (CNS) that needs for reliable biomarkers to foresee disease severity. Previous …

The choroid plexus is a new player in the gut-brain communication. Several pathologies are
associated to dysfunctions of either gut and choroid plexus epithelial and vascular barriers. …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immature cells
with a crucial role in regulating the immune response in multiple sclerosis (MS). Monocytic-…

Traumatic brain injury (TBI) is the leading cause of death and disability. Some TBI patients
develop chronic neuroinflammation, which can last several years after injury, so the role of …

Objective: To assess the impact of evobrutinib on classical dendritic cells (cDCs) in the
MOG 35–55 -induced chronic-progressive experimental autoimmune encephalomyelitis (EAE) …